#SABCS25: Rachel Freedman, MD | Dana-Farber Cancer Institute
#SABCS25: Dana-Farber Cancer Institute's Rachel Freedman, MD, presents results from the phase 2 ATOP study showing older patients with HER2+ breast cancer receiving adjuvant T-DM1 had a favorable 5-year survival with manageable toxicity. ATOP is the 1st adjuvant trial for older patients with HER2+ breast cancer in the United States. Video published 12/14/2025
🎬 More from Dana-Farber Cancer Institute
Understanding Chemo Neuropathy: A Webinar by the Older Adults with GI Cancer Program | Dana-Farber
19 views
Learning About Chronic Lymphocytic Leukemia | Lymph Notes: A Lymphoma Learning Series
112 views
ASCO26: David Reardon, MD Glioblastoma Vaccine | Dana-Farber Cancer Institute
106 views
Society of Gynaecological Oncology Congress 2026: Tara Berman, MD | Dana-Farber Cancer Institute
30 views
ASCO26: Julia Rotow, MD Silevertinib in Lung Cancer | Dana-Farber Cancer Institute
55 views
ASCO26: Atish Choudhury, MD, PhD A-DREAM/Alliance A032101 | Dana-Farber Cancer Institute
38 views